Validation of a reversed-phase HPLC method for 1,10-phenanthroline-5,6-dione and analysis of its impurities by HPLC-MS

Journal of Pharmaceutical and Biomedical Analysis

Volumn 33, Issue 2, 2003, Pages 219-230

  Shabir, Ghulam A ^a   Forrow, Nigel J ^a  

^a ABBOTT LABORATORIES   (United Kingdom)

Author keywords

1,10 Phenanthroline 5,6 dione; HPLC; HPLC MS; Method development; Method validation; Synthetic impurities

Indexed keywords

1,10 PHENANTHROLINE 5,6 QUINONE; 4,5 DIAZAFLUOREN 9 ONE; ANTIAMEBIC AGENT; ANTIINFECTIVE AGENT; ANTIPROTOZOAL AGENT; PHENANTHROLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG IMPURITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET SPECTROSCOPY; VALIDATION PROCESS;

EID: 0041324618     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0731-7085(03)00261-9     Document Type: Article

References (28)

1. Kradolfer F., Neipp L. Antibiot. Chemother. 8:1958;297.
2. Eckert T.S., Bruice T.C., Gainor J.A., Weinreb S.M. Proc. Natl. Acad. Sci. USA. 79:1982;2533.
3. Eckert T.S., Bruice T.C. J. Am. Chem. Soc. 105:1983;4431.
4. Itoh S., Kinugawa M., Mita N., Ohshiro Y. J. Chem. Soc., Chem. Commun. 1989;694.
5. Hilt G., Steckhan E. J. Chem. Soc., Chem. Commun. 1993;1706.
6. Itoh S., Fukushima H., Komatsu M., Ohshiro Y. Chem. Lett. 1992;1583.
7. European Patent Application, 1,023,455 (2 Aug 2000); WO 9,919,507 (22 April 1999).
8. Byrne H.A., Tieszen K.L., Hollis S., Dornan T.L., New J.P. Diabetes Care. 23:2000;500.
9. Smith G.F., Cagle F. J. Org. Chem. 12:1947;781.
10. Linker F., Evans R.L. J. Am. Chem. Soc. 68:1946;403.
11. Druey J., Schmidt P. Helv. Chim. Acta. 33:1950;1080.
12. British Patent, 688,802 (11 March 1953).
13. Imor S., Morgan R.J., Wang S., Morgan O., Baker A.D. Synth. Commun. 26:1996;2197.
14. Dickeson J.E., Summers L.A. Aust. J. Chem. 23:1970;1023.
15. Gillard R.D., Hill R.E.E., Maskill R. J. Chem. Soc. A. 1970;1447.
16. Yamada M., Tanaka Y., Yosimoto Y., Kuroda S., Shimao I. Bull. Chem. Soc. Jpn. 65:1992;1006.
17. Hiort C., Lincoln P., Nordén B. J. Am. Chem. Soc. 115:1993;3448.
18. Calderazzo F., Marchetti F., Pampaloni G., Passarelli V. J. Chem. Soc., Dalton Trans. 1999;4389.
19. Inglett G.E., Smith G.F. J. Am. Chem. Soc. 72:1950;842.
20. Mlochowski J. Rocz. Chem. 48:1974;2145.
21. Mlochowski J., Skrowaczewska Z. Rocz. Chem. 47:1973;2255.
22. Baxter P.N.W., Connor J.A., Wallis J.D., Povey D.C., Powell A.K. J. Chem. Soc., Perkin Trans. 1:1992;1601.
23. Zhong D., Blume H. Pharmazie. 49:1994;736.
24. Martens J. J. Chromatogr. B. 673:1995;183.
25. International conference on harmonisation: guidelines availability: impurities in new drug substances: Notice, Fed. Reg. 61 (1996) 371-376.
26. Prabhu S.V. Talanta. 40:1993;989.
27. Degen P.H., Brechbühler S., Schäublin J., Riess W. J. Chromatogr. A. 118:1976;363.
28. Guidelines for Collaborative Study Procedure to Validate Characteristics of a Method of Analysis, J. Assoc. Off. Anal. Chem. 72 (1989) 694-704.